Welcome to our dedicated page for Apollomics SEC filings (Ticker: APLM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollomics Inc. filings document the regulatory record of a foreign private issuer developing oncology therapies. Its Form 6-K reports furnish financial-results releases, clinical-development updates for vebreltinib (APL-101), material agreements and license matters, related-party convertible-note financing, collaboration updates, and operational-continuity disclosures.
The filing record also covers governance and control procedures, including director appointments and committee composition, auditor changes, registration-statement incorporation, and litigation-related disclosures. These filings place Apollomics' oncology pipeline, capital structure, public-company governance and risk matters into formal SEC-reporting categories.
Apollomics Inc. reported changes to its Board of Directors effective July 20, 2026. Directors Yi-An Chu and Dr. Chen-Huan (Jack) Jan resigned, and the company states these resignations were not related to any disagreement. The Board appointed Hung-Hsien Yen as a Class I director to fill the vacancy. He will also serve on the Audit Committee and as Chairman of the Nominating and Corporate Governance Committee.
Following these changes, the Board has six members, including four independent directors. Hung-Hsien Yen brings over 25 years of experience in private equity and direct investments and currently chairs SINO SUN CAPITAL INVESTMENT CO., LTD. His compensation includes 500 restricted stock units vesting on September 15, 2026, an annual cash retainer of $24,000, plus $5,000 for Audit Committee service and $10,000 for chairing the Nominating and Corporate Governance Committee. This information is incorporated by reference into Apollomics’ Form S-8 and Form F-3 registration statements.
Apollomics Inc. reports that Nasdaq has confirmed the company has regained compliance with the Market Value of Listed Securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market.
Nasdaq staff determined that from June 23, 2026 to July 7, 2026 Apollomics’ MVLS was $35 million or greater for 10 consecutive business days, following an earlier June 18, 2026 notice of non-compliance when MVLS had been below the required $35 million minimum for 30 consecutive business days. The matter is now closed. Apollomics is a late-stage clinical biopharmaceutical company whose lead program, vebreltinib (APL-101), is in a Phase 2 multicohort trial for cancers with c-Met alterations.
Apollomics Inc. reported that Nasdaq has notified the company it no longer meets the required Market Value of Listed Securities (MVLS) of $35 million for continued listing on The Nasdaq Capital Market. Apollomics has 180 days, until December 15, 2026, to restore compliance, and its shares continue trading under the symbol APLM during this period.
Separately, Apollomics terminated its Collaboration and License Agreement with Launxp International after Launxp failed to pay the remaining $3.8 million upfront balance plus interest. All licenses granted to Launxp ended immediately, and Apollomics has begun the contractually required dispute resolution process while seeking recovery of the unpaid amount. The company has regained rights to its lead drug candidate vebreltinib (APL‑101) across Asia, now holding global rights outside Mainland China and Macau.
Apollomics Inc. Chief Financial Officer Peter Kuan-How Lin reported routine equity compensation activity involving restricted stock units (RSUs). On June 15, 2026, 10,000 RSUs vested into Class A Ordinary Shares, reflecting previously granted awards that vest in four 10,000-share installments.
In connection with this vesting, 3,588 Class A Ordinary Shares were disposed of to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Lin held 22,312 Class A Ordinary Shares directly. The filing reflects compensation-related equity settlement, not a discretionary market purchase or sale.
Apollomics Inc. director and CEO Hung-Wen Chen reported equity compensation activity rather than open‑market trading. On June 15, 2026, 5,000 Restricted Stock Units vested, and he acquired 5,000 Class A Ordinary Shares at a price of $0.00 per share through a derivative exercise. Each RSU converts into one Class A Ordinary Share.
Following the transaction, Chen directly holds 148,334 Class A Ordinary Shares and has an indirect interest in 763,028 Class A Ordinary Shares held through King Regent Management Limited, where he has voting and dispositive power but disclaims beneficial ownership except for his pecuniary interest. After this vesting, 5,000 RSUs remain from the original grant, scheduled to vest on September 15, 2026.
Apollomics Inc. director CHU YI-AN acquired 500 Class A Ordinary Shares through the vesting and exercise of Restricted Stock Units (RSUs). The shares were issued at a price of $0.00 per share as part of previously granted equity awards.
Following this transaction, CHU YI-AN directly holds 1,500 Class A Ordinary Shares. The footnotes state that the initial RSU grant vested in four equal tranches of 500 shares, with three tranches (including this one on June 15, 2026) already vested and an additional 500 RSUs scheduled to vest on September 15, 2026.
Apollomics Inc. director Hong-Jung Chen exercised restricted stock units into common shares. On June 15, 2026, 500 Restricted Stock Units converted into 500 Class A Ordinary Shares at a stated price of $0.00 per share, increasing direct holdings to 3,620 Class A Ordinary Shares.
The RSUs were part of a previously disclosed grant. Footnotes explain that 500 RSUs vested on each of February 9, 2026, March 15, 2026 and June 15, 2026, and an additional 500 RSUs are scheduled to vest on September 15, 2026.
Apollomics Inc. director Tsai Hsien-Shu increased his direct equity stake through routine equity compensation. On June 15, 2026, 500 Restricted Stock Units vested, converting into 500 Class A Ordinary Shares at a price of $0.00 per share.
The RSUs were part of a prior grant under which 500 units vested on each of February 9, March 15, and June 15, 2026, with another 500 scheduled to vest on September 15, 2026. Following this transaction, Tsai directly holds 1,500 Class A Ordinary Shares and 500 remaining RSUs, reflecting standard compensation-related equity accrual rather than an open-market trade.
Apollomics Inc. director and COO Yi-Kuei Chen reported equity holdings and a routine RSU vesting. On June 15, 2026, he exercised 5,000 Restricted Stock Units at $0.00 per share, receiving 5,000 Class A Ordinary Shares, bringing his direct holdings to 15,000 shares.
He is also shown as having an indirect interest in 101,248 Class A Ordinary Shares through Maxpro Investment Co., Ltd., where he serves on the board and disclaims beneficial ownership except for his pecuniary interest. The RSUs involved in this filing were previously granted and disclosed on earlier Forms 3 and 3/A.
Apollomics Inc. director Jan Chen-Huan reported a routine equity compensation event, with 500 Restricted Stock Units vesting into 500 Class A Ordinary Shares on June 15, 2026. Each RSU represents a right to receive one Class A share. Following this vesting and related derivative exercise, Chen-Huan directly holds 1,500 Class A Ordinary Shares and 500 RSUs, with no open-market purchases or sales disclosed.